Evicenter
P&T meetings

Dersimelagon (MT-7117)

Erythropoietic protoporphyria or X-linked protoporphyria

Manufacturer
LEO Pharma
Regulatory submission
NDA submitted June 2026
Last updated
100 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology

Incidence of Erythropoietic protoporphyria or X-linked protoporphyria

2 evidence topics · 3 sources

Estimated incidence and rank among the porphyrias

“EPP is the third most common porphyria, with an estimated incidence of two to five in 1,000,000; it is the most common porphyria in children.” (opens the source at this quote in a new tab)

Incidence in the Italian national porphyria network, 1996 to 2017

“revealing a prevalence of 3.15 cases per million persons and an incidence of 0.13 cases per million persons/year” (opens the source at this quote in a new tab)

Incidence of X-linked protoporphyria

No evidence found.